Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Tissue Regenix Group PLC dCELL Dermis Produces Encouraging Results From Interim Clinical Data


Thursday, 4 Oct 2012 02:00am EDT 

Tissue Regenix Group PLC announced that the interim data from the clinical trial of Tissue Regenix Group plc ('Tissue Regenix') dCELL Dermis (application of human skin which has been treated with Tissue Regenix' dCELL process) has delivered very encouraging results. The trial, which is being conducted at University Hospital South Manchester, and involves 20 patients, has shown that treatment of chronic wounds with Tissue Regenix dCELL Dermis has led to a significant reduction in the size of all wounds, while 45% of patients have been completely healed. The trial, which is being conducted in partnership with NHS Blood and Transplant ('NHSBT'), and is due to complete by the end of the year, is studying the effectiveness of dCELL Dermis in treating chronic wounds, consisting primarily of venous leg ulcers that have failed to respond to standard treatments. Patients involved in the trial had, on average, suffered with chronic ulcers for more than four and a half years. The key findings from the interim study are: All but two patients have had a single application of dCELL dermis; All ulcers reduced in surface area (by an average of 50%) at the six-week point; Likewise, volume reduced significantly at the six-week point; Nine patients have been completely healed (study still ongoing). 

Company Quote

25.75
-1.0 -3.85%
16 Sep 2014